Cystic fibrosis drug gets PBS listing

About 250 Australians with a rare form of cystic fibrosis will gain access to $300,000-a-year drug ivacaftor (Kalydeco) when it is listed on the PBS from December.

The drug is effective in patients with the G551D mutation, which is about 5% of people with the disease. It deactivates the genetic defect and allows the body to break down and drain mucus in the lungs and digestive system.

Federal Health Minister Peter Dutton announced the PBS